American College of Cardiology 75th Annual Scientific Session & Expo (ACC.26)

New Orleans, Louisiana, US 28 March 2026 - 30 March 2026

Statin-ezetimibe holds slight advantage over PCSK9is in ACS

24 Apr 2026 by

In a systematic review and network meta-analysis (NMA), a statin-ezetimibe combination yields a more favourable LDL-C reduction and a positive trend in atherosclerotic plaque regression compared with PCSK9 inhibitors (PCSK9is) alone in individuals with acute coronary syndrome (ACS).

24 Apr 2026

Ultrasound-facilitated, catheter-directed thrombolysis beneficial in intermediate-risk PE

18 Apr 2026 by

In the treatment of patients with acute, intermediate-risk pulmonary embolism (PE), administering ultrasound-facilitated, catheter-directed thrombolysis (USCDT) on top of anticoagulation results in better short-term outcomes compared with anticoagulation alone, as shown in the multinational, adaptive-design, open-label HI-PEITHO trial.

18 Apr 2026

Transcatheter ViV may be a safe short-term option to repeat MVR

18 Apr 2026 by

The transcatheter valve-in-valve (ViV) procedure appears to be a safe option for select patients requiring repeat surgery after failed mitral bioprostheses, according to findings from the randomized controlled SURViV trial presented at ACC.26. However, it is still early days for the ViV approach.

18 Apr 2026

SURPASS-CVOT: Tirzepatide better than dulaglutide for cardiorenal outcomes

17 Apr 2026 by

Treatment with tirzepatide, a dual GLP-1* and GIP** agonist, significantly improves cardiovascular and renal outcomes in patients with diabetes and atherosclerotic cardiovascular disease (ASCVD) compared with dulaglutide, according to a post hoc analysis of the SURPASS-CVOT trial presented at ACC.26.

17 Apr 2026

SMART-DECISION: Stable post-MI patients can be safely taken off beta-blockers after 1 year

16 Apr 2026 by

Stopping beta-blockers after a year of regular use does not appear to increase the risk of adverse clinical outcomes in myocardial infarction (MI) survivors without evidence of left ventricular systolic dysfunction or heart failure (HF), as shown in the SMART-DECISION trial.

16 Apr 2026

Mavacamten reduces blood flow obstruction in adolescents with HCM

14 Apr 2026 by

Treatment with mavacamten, compared with placebo, results in significantly greater reduction in left ventricular outflow tract (LVOT) obstruction over 28 weeks among adolescent patients with obstructive hypertrophic cardiomyopathy (HCM), as shown in the SCOUT-HCM trial.

14 Apr 2026

More aggressive LDL-C reduction improves cardiac outcomes in ASCVD patients

13 Apr 2026 by

An intensive targeting of low-density lipoprotein cholesterol (LDL-C) level (<55 mg/dL) reduces the risk of cardiovascular events at 3 years in patients with atherosclerotic cardiovascular disease (ASCVD) when compared with conventional targeting (<70 mg/dL), results of the Ez-PAVE trial have shown.

13 Apr 2026

Clopidogrel vs aspirin maintenance post-PCI with DES: Which reigns better?

09 Apr 2026 by

Results from the 10-year follow-up of the HOST-EXAM* trial favour clopidogrel over aspirin as chronic maintenance therapy after percutaneous coronary intervention (PCI) with a drug-eluting stent (DES).

09 Apr 2026

Early intensive lipid-lowering with evolocumab cuts CV events in high-risk primary prevention patients

08 Apr 2026 by

In the prespecified subgroup analysis of the VESALIUS-CV trial, evolocumab significantly reduced the risk of first major adverse cardiovascular (CV) events (MACE) in individuals without known significant atherosclerosis and with diabetes.

08 Apr 2026